| Biomarker ID | 771 |
| PMID | 21980368 |
| Year | 2011 |
| Biomarker | miR-7-1*; miR-126*; miR-335; miR-28-5p; miR-339-3p; miR-339-5p; miR-542-5p |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated: [miR-7-1* (8.88 fold); miR-126* (3.46b fold); miR-335 (2,42 fold); miR-28-5p (6.84 fold); miR-339-3p (-1.57 fold); miR-339-5p (5.26 fold); miR-542-5p (13.31 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include (miR-126):- DNA-binding transcription factor activity, RNA polymerase II-specific; Gene expression (Transcription); RNA Polymerase II Transcription; Generic Transcription Pathway; nuclear chromatin Pathways Include(miR-28-5p):- synapse; nervous system development ; Golgi apparatus; cell junction; neuron projection Pathways Include(miR-339-3p):- generation of neurons; neurogenesis; nervous system development; synapse; neuron differentiation |
| Experiment | Metastatic Vs Non Metastatic |
| Type of Biomarker | Prognostic |
| Cohort | From 1 patient, metastatic versus a non-metastatic prostate cancer xenograft line were dervied. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | quantitative PCR (qPCR) |
| Clinical | No |
| Remarks | * indicates the less dominant arm in the miRNA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | miR-7-1*, miR-126*, miR-335, miR-28-5p, miR-339-3p, miR-339-5p, miR-542-5p |